Recent Publications by Valentis: |
The antiprogestin-dependent GeneSwitch system for regulated gene therapy.
Antiprogestin-controlled gene regulation systems, initially developed by... | 18th August, 2004
| Valentis, Inc., 863A Mitten Road, Burlingame, CA 94010, USA.
| Steroids. 2003 Nov;68(10-13):1085-94.
|
Regulated production of proteins from muscle using gene transfer: potential therapeutic applications.
The ability to produce high-level transgene expression following the... | 14th July, 2004
| Valentis, Inc, Burlingame, CA 94010, USA.
| Expert Opin Biol Ther. 2003 Apr;3(2):277-91.
DOI Direct Link |
Biodistribution and safety studies of hDel-1 plasmid-based gene therapy in mouse and rabbit models.
A plasmid encoding the human developmentally regulated endothelial locus-1... | 24th June, 2004
| Valentis,
| J Pharm Pharmacol. 2004 Feb;56(2):177-85.
DOI Direct Link |
Plasmid-based gene transfer and antiprogestin-controllable transgene expression.
Inhibition of the neovascularization of tumors has proven efficacious in... | 30th January, 2004
| Valentis, Inc., 8301 New Trails Drive, The Woodlands, TX 77381, USA.
| Ernst Schering Res Found Workshop. 2003;(43):225-44.
|
Antiprogestin-controllable transgene regulation in vivo.
Gene control systems that provide temporal and spatial regulation of... | 13th March, 2003
| Valentis,
| Curr Opin Biotechnol. 2002 Oct;13(5):453-8.
|
Poly-L-glutamate, an anionic polymer, enhances transgene expression for plasmids delivered by intramuscular injection with in vivo electroporation.
Intramuscular (i.m.) injection of plasmids followed by... | 26th November, 2002
| Valentis, Inc, The Woodlands, TX 77381-4248, USA.
| Gene Ther. 2002 Oct;9(20):1351-8.
DOI Direct Link |
